Search results
Arrowhead Pharmaceuticals Inc. [ARWR] Records 200-Day SMA of $27.99 – Knox Daily
Knox Daily· 2 days agoInvestors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Arrowhead Pharmaceuticals Inc. shares valued at $41,935 ...
Arrowhead's much-anticipated cholesterol drug hits the mark again in phase 2 hyperlipidemia trial
FierceBiotech· 4 days agoArrowhead Pharmaceuticals’ hotly anticipated cholesterol disorder drug lowered key lipoproteins that...
Arrowhead shares hold Outperform rating By Investing.com
Investing.com· 2 days agoOn Thursday, RBC (TSX:RY) Capital maintained its optimistic stance on Arrowhead Pharmaceuticals...
RNA Inhibitor Is Shown Safe and Effective in Reduc | Newswise
Newswise· 4 days agoNewswise — (New York, NY - May 29, 2024) – A small interfering RNA (siRNA) investigational therapy...
Triglycerides Down With ANGPTL3 RNA Interference Agent
MedPage Today· 4 days agoAn RNA interference therapy, targeting ANGPTL3 in the liver, drastically reduced fasting triglycerides in people with mixed hyperlipidemia, the ARCHES-2 trial showed. Used atop usual statins ...
Plozasiran Paves RNA Interference Path to Triglyceride Reduction
MedPage Today· 5 days agoThe liver APOC3-targeted RNA interference agent plozasiran proved its triglyceride-lowering effects...
BMO highlights Ionis Pharmaceuticals' market entry advantage in bullish stock rating By...
Investing.com· 3 days agoThe firm's outlook followed a comparison of Ionis's drug candidate, Olezarsen, with a competing...
Promising results for hyperlipidemia treatment reduce risk of cardiovascular events
Medical Xpress· 4 days agoThe results, published in the latest edition of the New England Journal of Medicine, demonstrate how the drug plozasiran works by targeting ApoC3, which is a key regulator of the lipoprotein ...
Tom Still: Founders can follow different strategies to entrepreneurial success
Wisconsin State Journal· 5 days agoOne Wisconsin example made news this week when Mirus Bio, one of the first biotechnology companies...
